Vyvanse (lisdexamfetamine dimesylate)

DRUG2 trials

Sponsors

Shire

Conditions

ADHDAttention Deficit Hyperactivity Disorder (ADHD)

Phase 3

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00500149

Start: 2007-06-13End: 2007-12-05Updated: 2021-06-14

Phase 4

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

CompletedNCT00500071

ShireAttention Deficit Hyperactivity Disorder (ADHD)

Start: 2007-06-28End: 2008-01-02Updated: 2022-03-10

Related Papers

Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.

2010-12-1421 citations

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.

2009-12-0136 citations

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

2009-06-0994 citations